Atlas Trials

De-escalation of Neoadjuvant Chemotherapy Regimens With Targeted Therapy Among HER2 Positive Patients

Clinical trial NCT06700369 · RECRUITING

Trial details

NCT number
NCT06700369
Sponsor
Shu Wang
Status
RECRUITING
Study type
OBSERVATIONAL
HER2-positive Breast Cancer
Start date
2015-01-01
Primary completion
2028-12-31
Enrollment
519

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.